特殊免疫研究所 Company Profile

In June 2023, the name for fatty liver disease was changed from NAFLD/NASH to MASLD/MASH. We have made a video available online that provides a detailed explanation of the diagnosis of MASLD/MASH, primarily aimed at primary care physicians and non-hepatology specialists. This video explains the overview of MASLD/MASH, the diagnostic methods for MASH, and how to identify high-risk groups using data and images. Our company is introducing this video as part of our awareness activities related to the disease.

We would like to inform you that starting from June 9, 2024, we have begun publishing new contracted services on our website. Please access the following link to view them: https://www.tokumen.co.jp/antibody/introduced-product/

We are pleased to announce that the research theme on diagnostic technology using biomarkers for early-stage liver cancer, in which our company and Perseus Proteomics Co., Ltd. are participating, and which is led by Associate Professor Koji Yamada from the Department of Biochemistry at Tokyo Medical University, has been selected for the "Innovative Cancer Medical Practical Research Project" publicly solicited by the Japan Agency for Medical Research and Development (AMED). For more details, please visit our company's website.